75 results about "Protective drugs" patented technology

The invention relates to a purifying method for a Rebamipide crude product. Alkaline is added in alcohol-water mixed solvent to dissolve the Rebamipide crude product. Then, activated carbon is added for decolorizing. Concentrated hydrochloric acid is added dropwise, pH is regulated to 2-3, solids are precipitated, and purified Rebamipide is obtained after filtering and drying. During the process, the mol ratio of the added amount of alkaline to the Rebamipide is controlled to be less than 3 to 1. And the operational temperature during the alkaline adding for dissolution and the acid adding for crystallization is controlled at 150 DEG C; therefore; the ring cleavage reaction of quinolone is inhabited and the generation of two impurities which are similar in structure with Rebamipide is reduced. Rebamipide with the purity of higher than 99.5 percent is obtained. Conditions are provided for improving the application degree of Rebamipide in pharmaceutical aspects of gastric mucosal protective drugs, etc.

The invention discloses a plant protection product, which is prepared from yellow extracellular polysaccharide bacterium and a copper inorganic salt in a coordinated complexing manner, or prepared from the yellow extracellular polysaccharide bacterium and a zinc inorganic salt in the coordinated complexing manner, or prepared from the yellow extracellular polysaccharide bacterium and the copper inorganic salt and the zinc inorganic salt in the coordinated complexing manner. The plant protection product is concretely prepared from the following components by weight percent: 0.5-1.0% of yellow extracellular polysaccharide bacterium, 0.5-1.0% of copper sulfate, 0.5-1.0% of zinc sulfate, 1% of polyethylene glycol-4000, 2% of polyving akohol, 1% of polyvinylpyrrolidone and 93.0-95.0% of distilled water. By adopting the plant protection product, the problem of poor blending property of an inorganic copper preparation is overcome, so that a compact protective drug film is formed after the inorganic copper preparation is sprayed on the crop surface, and copper and zinc ions are subjected to sustained release to be taken as plant nutrients, so that the low 'copper content' in the preparation is ensured, and the problems of copper pollution or aggravated mite pollution caused by incorrect use of the inorganic copper preparation is overcome.

An occlusion catheter for the ascending aorta capable of obstructing the blood flow within the ascending aorta without inserting through the femoral artery. The occlusion catheter is provided with a drug release aperture formed in the region, which is closer to the proximal end of the catheter tube than a balloon on the outer circumference of the distal end and which is to be located in the vicinity of the coronary ostium when the balloon is placed within the ascending aorta. The present occlusion catheter, when inserted directly into the ascending aorta in the vicinity of the heart to obstruct the blood flow therewithin, enables delivery of a cardiac muscle protective drug to the vicinity of the coronary ostium without inserting the occlusion catheter through the femoral artery in the conventional manner.

The present invention provides improved systems, methods and software for determining a pathway activation strength in old subjects relative to young subjects of the same species, the method including collecting young subject transcriptome data and old subject transcriptome data for one species to evaluate pathway activation strength (PAS) and down-regulation strength for a plurality of biological pathways, mapping the plurality of biological pathways for the activation strength and down-regulation strength from old subject samples relative to young subject samples to form a pathway cloud map and providing a gero-protective rating for each of a plurality of drugs in accordance with a drug rating for minimizing signaling pathway cloud disturbance (SPCD) in the pathway cloud map of the one species to provide a ranking of the gero-protective drugs.

The invention discloses an application of Pedinophyllol B in preparation of a vascular protective drug and belongs to the field of drugs. MTT (methyl thiazolyl tetrazolium) assay and LDH (lactic dehydrogenase) activity detection prove that Pedinophyllol B has an protective effect on H2O2 oxidative damage ECV-304 cells; measurement for MDA (malondialdehyde) content, SOD (superoxide dismutase) activity and GSH-Px (glutathion peroxidase) activity of a cell supernatant proves that Pedinophyllol B has the free radical scavenging property and the antioxidant property of active oxygen and can be further researched and developed to prepare the vascular protective drug.

The invention belongs to the technical field of medicine and pharmacology and discloses a protective drug for D-GaIN/LPS induced liver injury. The protective drug for induced liver injury is daucosterol. It is indicated herein that daucosterol has anti-inflammatory and immunoregulatory activities; daucosterol may promote generation of CD4+T cells to assist a mouse to resist disseminated candidiasis when used to treat the mouse with disseminated candidiasis; a mouse model with galactosamine lipoxygenase induced liver injury is commonly used to analyze pyemic liver injury; daucosterol is used herein to intervene the mouse model with D-GaIN/LPS induced liver injury, the protective action and possible mechanism of daucosterol against D-GaIN/LPS induced liver injury is explored, and daucosterolis significant to analyze a drug to treat pyemia.

The invention relates to new application of cytochalasin H in pharmacy, and particularly relates to the application of the cytochalasin H in preparation of Parkinson's disease resistant nerve-protective drugs. A series of in-vitro tests certificates that the cytochalasin H has significant protective effects on PC12 cellular damage induced by MPP +, and can be used to develop the Parkinson's disease resistant drugs.

The invention relates to a dual-functional radiation damage protection drug containing phenols and synthesis and application thereof. Phenolic compound acting as radiation protection drug is carried out in a stoichiometric ration of 1:1, so there is nothing to do about damage arising from high-dose and continuous radiation. The related compound in the invention has a structure as described in the description, wherein at least one of R1-R5 is OH, while others are respectively selected from H, OCH3, NO2, and X, and n is 1 or 2. The drug has outstanding protection effect on damages caused by ionizing radiation and non-ionizing radiation, has a similar control effect with anti-radiation drug WR2721 in current market, however, the drug has lower toxicity, and can be used in the protection against damage caused by high-dose and continuous radiation.

The invention provides drug screening methods and methods for determining efficacy of a therapeutic regimen in humans. In particular, the invention provides screening methods to determine efficacy of a therapeutic regimen to protect human subjects from deleterious effects of cytotoxic agents. The inventive method comprises i) extracting target cells from the human subject prior to exposure to a cytotoxic agent, ii) treating the subject with a cytotoxic protective drug; iii) extracting the target cells from the subject after treatment with the cytotoxic protective drug of step ii); iv) exposing the target cells of steps i) and iii) to the cytotoxic agent; and v) analyzing and comparing one or more parameters indicative of viability and growth conditions in target cells of step i) and step iii), wherein a favorable viability and growth condition of the target cells of step iii) as compared to target cells of step i) is indicative of the efficacy of the therapeutic regimen in the human subject.

The invention discloses a use of lachnum intracellular melanin serving as an acute liver injury medicine. The intracellular melanin LIM30 is prepared from lachnum with a culture preservation serial number of CCTCC No:M2011054, pharmacological experiments prove that the lachnum intracellular melanin LIM30 can greatly improve the liver indexes of mice subjected to acute liver injury, reduce the levels of ALT and AST, reduce the content of NF-K, reduce the inflammatory factors and inflammation related cytokines and has good anti-inflammatory and hepatoprotective effects; and in addition, LIM30 can increase anti-inflammatory cytokine levels in serum of the mice. The LIM30 is free of toxic or side effects, can be used for preparing anti-inflammatory and liver protective drugs, and can be prepared into all kinds of forms according to the conventional preparation methods of pharmaceutics, and is easy to take.

The present invention discloses a fibrinolysim enzyme modifying with carbowax and the preparation method; the present invention is characterized in that the amino group of the fibrinolysim enzyme is modified with activatory carbowax or the ramification strand of the carbowax. The present invention of fibrinolsim enzyme modifying with carbowax can basically preserves the biological value of the fibrinolysim enzyme; meanwhile, the present invention has low immunogenic and greater stability as compared with the fibrinolysim enzyme which is unmodified; therefore, the pharmacokinetics of the fibrinolysim enzyme is improved and the tolerance is increased and the administration times is reduced. The present invention also discloses the application of fibrinolysim enzyme modifying with carbowax in the preparation of high-efficiency low-toxin drug of dissolving thrombus and nervous protective drug.

The invention discloses application of a protosappanin A derivative in protecting cardiac trauma caused by chemotherapeutics. A chemical formula of the protosappanin A derivative is as shown in general formula I. Action and a mechanism of protecting cardiac trauma, induced by chemotherapeutics adriamycin, by the protosappanin A derivative are researched; research results show that the protosappanin A derivative can relieve cardiac trauma as well as myocardium cell apoptosis and oxidative stress injury induced by the adriamycin, and can be used as a heart protective drug. The invention discloses a novel and effective treatment way for treating or preventing cardiac trauma caused by chemotherapeutics.

The invention relates to a disposable protective drug dispenser which comprises a protective shell, a middle partition and a puncture inserting rod. The puncture inserting rod is provided with sharp tips at two ends and penetrates through the middle partition. Two drug mixing passages with staggered openings are arranged in the puncture inserting rod. Elastic liquid-blocking rubber sleeves are hermetically sleeved on the puncture inserting rod parts on two sides of the middle partition. The puncture inserting rod parts on two sides of the middle partition are inserted into a drug mixing bottle and a drug dispensing bottle respectively. During inserting and drawing of the puncture inserting rod, the elastic liquid-blocking rubber sleeves spring back timely due to elasticity to seal liquid inlets of the puncture inserting rod so as to prevent leakage of liquid drugs and protect medical staff from being stabbed by sharp apparatus. The disposable protective drug dispenser is simple in structure, convenient for drug dissolving and drug dispensing, simple and laborsaving to operate and safe and reliable to use. Contact of medical staff with sharp tips of the drug dispenser is avoided, and adverse influence, caused by leakage of drug ingredients, on medical staff is avoided.

The present invention provides for therapies characterized in part by co-administration or combination of antibiotic agents with medicinal compositions comprising as the pro-antibiotic active ingredient either a compound represented by a formula [I] or a pharmaceutically acceptable composite thereof; [wherein X represents oxygen, sulfur, NH, or N-alkyl; R₁ and R₂ represent hydrogen, tetrazole, or alkyltetrazole, respectively (with the restriction that if R₁ is not hydrogen, R₂ must be, and vice versa); R₃ represents e.g., benzyl, phenyl optionally substituted, biphenyl, napthyl, N-phenylcarboxamido, etc., R₄ represents e.g. carboxylic acid, or its alkyl esters, or a bioisoteric equivalent thereof, etc.; R₅ represents e.g. hydrogen, carboxylic acid, etc.] in particular, medicine which is useful as therapeutic and/or protective drugs for infectious and/or inflammatory diseases. Other relevant compounds are also provided.

Belonging to the biotechnology field, the invention relates to new application of taurine, in particular to application of taurine in preparing a preparation for detecting or preventing myocardial ischemia injury. The results of animal level and cellular level experiments show that during acute myocardial ischemia, the content of taurine in myocardial cells decreases, after rendering exogenous taurine, an effect against the myocardial ischemia induced cell apoptosis is generated, thus achieving the effect of protecting acute myocardial ischemia. Experiments show that taurine can serve as a detection marker of acute myocardial ischemia, pretreatment has a protective treatment effect on acute myocardial ischemia, and further can be used for preparing a preparation detecting myocardial ischemia. Experiments also show that the taurine can resist myocardial ischemia induced cell apoptosis so as to play a protection role, and further can be used for preparation of protective drugs preventing and treating acute myocardial ischemia.

The invention discloses application of herpetrione or an extract whose main effective component is herpetrione in preparation of a medicine for treating a non-alcoholic fatty liver disease. A extraction method comprises the following steps: crushing herpetospermum pedunculosum seeds, extracting with 95% ethanol, extracting the extracting solution with ethyl acetate, and concentrating under reduced pressure to obtain extract. Experiments show that herpetrione can remarkably reverse rise of levels of liver function indexes ALT and AST in serum of non-alcoholic fatty liver disease C57BL/6J mice induced by methionine-choline deficiency diet, serum inflammatory factors IL-6 and IL-1beta, TG in liver tissue and the like, reverse reduction of an HDL index, weight of the mice and a liver index, and improve fat lesion of the liver tissue, and has a significant protective effect on liver damage. The invention broadens application range of herpetrione or herpetospermum pedunculosum seed ethyl acetate extract, and has important application value and economic benefits for the development of protective drugs for liver damage.

The invention discloses an integrated protective drug delivery window convenient to operate. The integrated protective drug delivery window comprises a box body, a visual interphone, a detector and a controller, wherein the box body comprises an upper delivery port and a lower delivery port; the upper delivery port and the lower delivery port penetrate through the box body; an upper shielding door is arranged between the two ends of the upper delivery port and the box body; a lower shielding door is arranged between the two ports of the lower delivery port and the box body. According to the integrated protective drug delivery window disclosed by the invention, the condition that hospital staff deliver drugs or other articles to patients in a non-contact manner is realized by the visual interphone, and the risk of infection is avoided; the upper delivery port and the lower delivery port on the box body adopt a bidirectional design, and the shielding doors are arranged in two directions, so that the use safety is improved, and the condition that a sterilization area cannot be formed due to unidirectional door opening is avoided; and the bidirectional shielding doors are arranged, so that the upper delivery port and the lower delivery port form a sealed bin, the propagation of bacteria is avoided, and the safety between doctors and the patients is improved.

The invention discloses a food packaging bag comprising a food layer tightly attached to food, an isolation layer and at least three vacuum layers used for conducting protective drug filling in sequence from inside to outside. Multiple vacuum cells used for loading a protective drug are evenly distributed on the vacuum layers. The vacuum cells on each vacuum layer are flush with the vacuum cells of the other two layers. The protective drug comprises, by weight, 4-6 parts of Melia azedarach L., 4-6 parts of Polygonum hydropiper, 4-6 parts of Herba Centellae, 5-7 parts of celery, 6-8 parts of Litsea cubeba(Lour.)Pers.[Laurus cubeba Lour.], 7-9 parts of grapefruit peel and 5-7 parts of lemons. The food packaging bag can expel parasites and cockroaches and can protect the food in the food packaging bag against damage.